Cas:117666-94-1 Boc-D-4-benzoylphenylalanine manufacturer & supplier

Chemical Name:Boc-D-4-benzoylphenylalanine

CAS.NO:117666-94-1

Synonyms:Boc-D-Bpa-OH;N-(tert-Butoxycarbonyl)-4-(phenylcarbonyl)-L-phenylalanine;(2R)-3-(4-benzoylphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid;L-Phenylalanine, 4-benzoyl-N-[(1,1-dimethylethoxy)carbonyl]-;(2S)-3-(4-Benzoylphenyl)-2-({[(2-methyl-2-propanyl)oxy]carbonyl}amino)propanoic acid;MFCD00237572;N-(tert-Butoxycarbonyl)-4-(phenylcarbonyl)-L-phenylalanin;(R)-3-(4-Benzoylphenyl)-2-((tert-butoxycarbonyl)amino)propanoic acid;4-Benzoyl-N-(tert-butoxycarbonyl)-L-phenylalanine;4-Benzoyl-N-{[(2-methyl-2-propanyl)oxy]carbonyl}-L-phenylalanine;Boc-D-4-benzoylphenylalanine

Molecular Formula:C₂₁H₂₃NO₅

Molecular Weight:369.411

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:561.4±50.0 °C at 760 mmHg

Density:1.2±0.1 g/cm3

Index of Refraction:1.567

PSA:92.70000

Exact Mass:369.157623

LogP:3.92

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like Boc-D-Bpa-OH chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Boc-D-4-benzoylphenylalanine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-(tert-Butoxycarbonyl)-4-(phenylcarbonyl)-L-phenylalanin Use and application,4-Benzoyl-N-(tert-butoxycarbonyl)-L-phenylalanine technical grade,usp/ep/jp grade.

Related News: After this long manufacturing process, it is purified until it reaches a very high degree of purity and finally becomes an API. Boc-D-4-benzoylphenylalanine manufacturer As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL. Boc-D-4-benzoylphenylalanine supplier The memo denies the company made false statements to the FDA. In their complaint, employees said they were broadly concerned that quality control documents the FDA requires companies to maintain had been rewritten or fabricated. The employees did not specify whether these materials had been shown to the FDA. Boc-D-4-benzoylphenylalanine vendor As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL. Boc-D-4-benzoylphenylalanine factory After this long manufacturing process, it is purified until it reaches a very high degree of purity and finally becomes an API.